Actively Recruiting
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
Led by ContextVision AB · Updated on 2025-12-08
110
Participants Needed
1
Research Sites
58 weeks
Total Duration
On this page
Sponsors
C
ContextVision AB
Lead Sponsor
U
University of Washington
Collaborating Sponsor
AI-Summary
What this Trial Is About
The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD). Current tests, like MRI or biopsy, can be expensive or invasive. If successful, this ultrasound tool could become an easier and more accessible way to monitor liver health - especially for people with obesity, diabetes, high blood pressure, or high cholesterol.
CONDITIONS
Official Title
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 to 75 years
- Willingness and ability to provide consent to participate in the study
- Diagnosed or suspected MASLD from a hepatology clinic OR belonging to a high-risk group with diabetes, obesity (BMI ≥ 25 kg/m²), high cholesterol, or high blood pressure
- Healthy volunteers aged 18 to 75 years with no suspicion of MASLD based on lab, imaging, or clinical exams
- Healthy volunteers without known metabolic conditions such as metabolic syndrome, diabetes, obesity, insulin resistance, or dyslipidemia
You will not qualify if you...
- Pregnancy or nursing
- Contraindications to MRI such as severe claustrophobia, pacemaker, or metallic/mechanical implants
- Acute illness or cognitive impairment preventing cooperation with MRI and ultrasound breath-holding instructions
- Body mass index (BMI) greater than 35 kg/m²
- History of excessive alcohol consumption or drug use within the past 2 years
- Known acute or chronic hepatitis or other liver diseases
- Presence of congenital liver anomalies
- Known cirrhosis
- Known active cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Washington
Seattle, Washington, United States, 98195
Actively Recruiting
Research Team
L
Laura Sissons-Ross Research Manager
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here